40751-88-0

Usage

Uses

Used in Organic Synthesis:
2-Methoxy-3-nitrobenzoic acid is used as a key intermediate in the synthesis of various organic compounds due to its unique structural features and reactivity. Its presence of both electron-donating and electron-withdrawing groups makes it a valuable component in the creation of complex organic molecules.
Used in Pharmaceutical Compounds:
As a building block for pharmaceuticals, 2-Methoxy-3-nitrobenzoic acid is utilized in the development of new drugs. Its chemical properties allow for the formation of diverse medicinal compounds with potential therapeutic effects.
Used in Dye and Pigment Production:
2-Methoxy-3-nitrobenzoic acid is used as a precursor in the production of dyes and pigments. Its chemical structure contributes to the color characteristics of these products, making it an essential component in the colorant industry.
Used in Medicine:
2-Methoxy-3-nitrobenzoic acid is being studied for its potential pharmacological properties. Its applications in medicine may include the development of new therapeutic agents, given its chemical versatility and the possibility of modifying its structure to target specific biological pathways.
Used in Agriculture:
In the agricultural sector, 2-Methoxy-3-nitrobenzoic acid may find use in the development of agrochemicals, such as pesticides or herbicides, where its chemical properties could be harnessed to control or manage pests and weeds effectively.
Used in Materials Science:
2-METHOXY-3-NITROBENZOIC ACID's potential applications in materials science include its use in the development of new materials with specific properties, such as those with enhanced stability, reactivity, or other desirable characteristics for various industrial applications.

Upstream product

• 186581-53-3 diazomethane 
• 85-38-1 3-nitrosalicylic acid 
• 18102-29-9 2-methyl-6-nitroanisole 
• 579-75-9 2-Methoxybenzoic acid 
• 77-78-1 dimethyl sulfate 
• 7664-93-9 sulfuric acid 
• 7697-37-2 nitric acid 
• 108-24-7 acetic anhydride 
• 22065-49-2 2-methoxy-3-nitro-benzaldehyde 
• 7722-84-1 dihydrogen peroxide 
• 67-64-1 acetone 
• 317-46-4 2-fluoro-3-nitro-benzoic acid 
• 124-41-4 sodium methylate 
• 22621-41-6 2-hydroxy-3-nitro-benzoic acid methyl ester 

Downstream Products

• 90564-26-4 2-methoxy-3-nitro-benzoic acid methyl ester 
• 105337-55-1 N-(3-amino-2-methoxy-benzoyl)-L_s-threonine 
• 85-38-1 3-nitrosalicylic acid 
• 912577-35-6 benzyl 2-methoxy-3-nitrobenzoate 
• 90923-07-2 ethyl 2-methoxy-3-nitrobenzoate 
• 1068432-32-5 methyl 2-methoxy-3-(2-methoxy-3-(2-methoxy-3-(2-methoxy-3-nitrobenzamido)benzamido)benzamido)benzoate 
• 1068432-34-7 methyl 2-methoxy-3-(2-methoxy-3-(2-methoxy-3-(2-methoxy-3-(2-methoxy-3-nitrobenzamido)benzamido)benzamido)benzamido)benzoate 
• 1068432-30-3 methyl 2-methoxy-3-(2-methoxy-3-(2-methoxy-3-nitrobenzamido)benzamido)benzoate 
• 1068432-28-9 methyl 2-methoxy-3-(2-methoxy-3-nitrobenzamido)benzoate 
• 1220387-56-3 C₁₈H₁₈N₂O₈ 
• 2554-86-1 2-methoxy-3-nitro-benzoyl chloride 
• 861306-04-9 3-amino-2-methoxybenzoic acid 
• 1437872-84-8 N-(2-(benzyloxy)phenyl)-2-methoxy-3-nitrobenzamide 
• 1437872-90-6 N-(2-(benzyloxy)phenyl)-2-methoxy-3-(2-methoxy-3-nitrobenzamido)benzamide 

Relevant academic research and scientific papers

COMPOUNDS AND METHODS FOR INHIBITING VIRAL REPLICATION AND METHODS OF TREATING AND PREVENTING FLAVIVIRAL INFECTIONS

The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present disclosure further relates to methods of inhibiting viral replication including contacting one or more cells that have been infected wit

Compound used as CDK7 kinase inhibitor and application thereof

The invention relates to a compound used as a CDK7 kinase inhibitor and application thereof. Specifically, the compound disclosed by the invention has a structure shown as a formula I, and the definitions of all groups and substituents are as described in the specification. The compounds of the present invention are useful as inhibitors of cyclin-dependent kinase 7 (CDK7) for the treatment or prevention of proliferative diseases such as cancer, especially for modulating and treating diseases associated with abnormal activity of cyclin-dependent kinase 7 (CDK7).

AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO THE MODULATION OF IL-12, IL-23 AND/OR IFN-ALPHA

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-2

JMX0207, a Niclosamide Derivative with Improved Pharmacokinetics, Suppresses Zika Virus Infection Both in Vitro and in Vivo

Flaviviruses causes significant human disease. Recent outbreaks of the Zika virus highlight the need to develop effective therapies for this class of viruses. Previously we identified niclosamide as a broad-spectrum inhibitor for flaviviruses by targeting

Drug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer

Metastasis is the cause of 90% of mortality in cancer patients. For metastatic colorectal cancer (mCRC), the standard-of-care drug therapies only palliate the symptoms but are ineffective, evidenced by a low survival rate of ～11%. T-cell factor (TCF) transcription is a major driving force in CRC, and we have characterized it to be a master regulator of epithelial-mesenchymal transition (EMT). EMT transforms relatively benign epithelial tumor cells into quasi-mesenchymal or mesenchymal cells that possess cancer stem cell properties, promoting multidrug resistance and metastasis. We have identified topoisomerase IIα (TOP2A) as a DNA-binding factor required for TCF-transcription. Herein, we describe the design, synthesis, biological evaluation, and in vitro and in vivo pharmacokinetic analysis of TOP2A ATP-competitive inhibitors that prevent TCF-transcription and modulate or reverse EMT in mCRC. Unlike TOP2A poisons, ATP-competitive inhibitors do not damage DNA, potentially limiting adverse effects. This work demonstrates a new therapeutic strategy targeting TOP2A for the treatment of mCRC and potentially other types of cancers.

SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF

The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compo

ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES

Compounds having the following formula I: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on Tyk-2 to cause signal transduction inhibition.

ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNALPHA RESPONSES

Compounds having the following formula (I): or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on Tyk-2 to cause signal transduction inhibition.

AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition.

ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES

Compounds having the following formula (I): or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.